5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
cases O
of O
dysphagia O
, O
bowel O
obstruction O
, O
and O
perforation O
have O
been O
associated O
with O
sevelamer O
use O
, O
some O
requiring O
hospitalization O
and O
surgery O
. O

( O
5.1 O
) O
5.1 O
Gastrointestinal B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
Cases O
of O
dysphagia B-OSE_Labeled_AE
and O
esophageal B-OSE_Labeled_AE
tablet I-OSE_Labeled_AE
retention I-OSE_Labeled_AE
have O
been O
reported O
in O
association O
with O
use O
of O
the O
tablet O
formulation O
of O
sevelamer O
, O
some O
requiring O
hospitalization O
and O
intervention O
. O

Consider O
using O
sevelamer O
suspension O
in O
patients O
with O
a O
history O
of O
swallowing B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Cases O
of O
bowel B-OSE_Labeled_AE
obstruction O
and O
perforation I-OSE_Labeled_AE
have O
also O
been O
reported O
with O
sevelamer O
use O
. O

Patients O
with O
dysphagia B-Not_AE_Candidate
, O
swallowing B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
severe O
gastrointestinal B-Not_AE_Candidate
( I-Not_AE_Candidate
GI I-Not_AE_Candidate
) I-Not_AE_Candidate
motility I-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
including O
severe O
constipation B-Not_AE_Candidate
, O
or O
major O
GI O
tract O
surgery O
were O
not O
included O
in O
the O
Renvela O
clinical O
studies O
. O

5.2 O
Reductions O
in O
Vitamins O
D O
, O
E O
, O
K O
( O
clotting O
factors O
) O
and O
Folic O
Acid O
Levels O
In O
preclinical O
studies O
in O
rats O
and O
dogs O
, O
sevelamer O
hydrochloride O
, O
which O
contains O
the O
same O
active O
moiety O
as O
sevelamer O
carbonate O
, O
reduced B-NonOSE_AE
vitamins O
D O
, O
E O
, O
and O
K O
( O
coagulation O
parameters O
) O
and O
folic I-NonOSE_AE
acid I-NonOSE_AE
levels I-NonOSE_AE
at O
doses O
of O
6-10 O
times O
the O
recommended O
human O
dose O
. O

In O
short-term O
clinical O
trials O
, O
there O
was O
no O
evidence O
of O
reduction B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
levels I-NonOSE_AE
of I-NonOSE_AE
vitamins I-NonOSE_AE
. O

However O
, O
in O
a O
one-year O
clinical O
trial O
, O
2 B-OSE_Labeled_AE
5 I-OSE_Labeled_AE
- I-OSE_Labeled_AE
hydroxyvitamin I-OSE_Labeled_AE
D I-OSE_Labeled_AE
( O
normal O
range O
10 O
to O
55 O
ng/mL O
) O
fell I-OSE_Labeled_AE
from O
39 O
+/- O
22 O
ng/mL O
to O
34 O
+/- O
22 O
ng/mL O
( O
p O
< O
0.01 O
) O
with O
sevelamer O
hydrochloride O
treatment O
. O

Most O
( O
approximately O
75 O
% O
) O
patients O
in O
sevelamer O
hydrochloride O
clinical O
trials O
were O
receiving O
vitamin O
supplements O
. O

